What this article covers
A clinical overview of the five most advanced pipeline obesity medications, why the next 5 years represent an unprecedented leap in treatment options, and what patients should do while the pipeline develops.
The field of pharmacological obesity treatment has advanced more in the past five years than in the preceding fifty. Semaglutide and tirzepatide produced weight loss outcomes that were previously considered impossible through medication. And the drugs in development right now may push that ceiling further still.
This is not speculative. These are drugs in Phase 3 clinical trials — large, rigorous studies with thousands of participants — with published Phase 2 data already showing weight loss of 20-24% of body weight. The question is no longer whether these drugs will exist. It's when they'll be available, who they'll be most appropriate for, and what patients should do in the meantime.
The Five Drugs That Will Define the Next Era
| Drug | Developer | Phase | Mechanism | Avg Weight Loss | Est. Approval |
|---|---|---|---|---|---|
| Retatrutide | Eli Lilly | Phase 3 | GLP-1/GIP/GCG | ~24% | 2027-2028 |
| CagriSema | Novo Nordisk | Phase 3 | GLP-1+Amylin | 22.7% | 2026-2027 |
| Orforglipron | Eli Lilly | Phase 3 | GLP-1 (oral) | ~15% | 2026-2027 |
| MariTide | Amgen | Phase 3 | GLP-1/GIP block | ~20% | 2027-2028 |
| Amycretin | Novo Nordisk | Phase 2 | GLP-1+Amylin (oral) | ~13% (12wk) | 2029-2030 |
Why Triple Agonism Changes the Calculus
Every prior weight loss medication worked by modulating a single pathway. GLP-1 receptor agonists were the first exception — they combined appetite suppression, gastric slowing, and glucose regulation in one mechanism. Tirzepatide added GIP. Retatrutide adds glucagon.
The glucagon component is significant not because glucagon causes weight loss on its own — it doesn't. But at the doses used in combination GLP-1 drugs, glucagon receptor activation increases resting metabolic rate and promotes lipolysis (fat breakdown directly from fat cells). The combination of eating less (GLP-1) and burning more (glucagon) in the same molecule is mechanistically distinct from anything currently approved.
The Oral GLP-1 Revolution
The most significant access story of the next five years may not be efficacy — it's oral administration. Rybelsus exists as oral semaglutide, but its food timing requirements and ~5-8% efficacy make it a limited option. Orforglipron and amycretin represent a different approach: small molecule designs that don't require peptide delivery mechanisms.
Current approved options achieve 15-22% weight loss. Start now, not later.
Get My Match →What This Means for Patients Today
The honest clinical recommendation: don't wait. The drugs currently available — particularly tirzepatide at 20-22% average weight loss — are genuinely excellent. They're available now. Starting treatment today doesn't prevent switching to newer options when they become available. And two years of treatment with tirzepatide represents substantial health benefit that waiting for retatrutide would forfeit.
The drugs coming in 2026-2028 are meaningfully better, but the difference between 20% and 24% weight loss is smaller than the difference between 0% and 20%.
Explore the full pipeline at the future GLP-1 hub, see the approval timeline, or compare all drugs at the comparison hub.
Frequently Asked Questions
Will there be a GLP-1 drug that causes 30%+ weight loss?
Retatrutide Phase 2 showed that 26% of participants lost 30% or more. Whether this holds in Phase 3 is unknown. The ceiling is moving, but we don't know yet where it lands.
Will GLP-1 drugs become cheaper by 2030?
Likely. Multiple drugs entering the market increases competition. Biosimilar semaglutide is expected to enter by 2026-2027, which should reduce costs substantially for current medications.
What is the most promising drug in the pipeline?
Retatrutide has the highest Phase 2 weight loss data (~24%). CagriSema has the strongest Phase 3 data (22.7%). Orforglipron may have the broadest access potential as an oral pill.
Ready to find your match?
Answer 5 quick questions and see licensed GLP-1 programs available in your state — matched to your budget. Free. No obligation.
Get My Match — Free →